Optimizing doses of a first line chemotherapy treatment containing epirubicin, paclitaxel and capecitabine (TEX) in metastatic breast cancer.

被引：0
|
作者：
Einbeigi, Z
Bergström, D
Hatschek, T
Malmberg, M
机构：
[1] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[2] Roche AB, Stockholm, Sweden
[3] Karolinska Hosp, S-10401 Stockholm, Sweden
[4] Helsingborg Hosp, Helsingborg, Sweden
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
539
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [21] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    [J]. Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
  • [22] Improved progression-free survival from the addition of vinorelbine to epirubicin in first line chemotherapy of metastatic breast cancer.
    Ejlertsen, B
    Mouridsen, HT
    Langkjer, ST
    Andersen, J
    Sjostrom, J
    Kjaer, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 270 - 270
  • [23] Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.
    Dufresne, A.
    Pivot, X.
    Colin, P.
    Bosset, M.
    Tournigand, C.
    Alwegg, T.
    De Grammont, A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S280 - S281
  • [24] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    Cappuzzo, F
    Mazzoni, F
    Gennari, A
    Donati, S
    Salvadori, B
    Orlandini, C
    Cetto, GL
    Molino, A
    Galligioni, E
    Mansutti, M
    Tumolo, S
    Lucentini, A
    Valduga, F
    Bartolini, S
    Crinò, L
    Conte, PF
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
  • [25] Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
    Sudeep Gupta
    [J]. Nature Clinical Practice Oncology, 2005, 2 : 80 - 81
  • [26] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    F Cappuzzo
    F Mazzoni
    A Gennari
    S Donati
    B Salvadori
    C Orlandini
    G L Cetto
    A Molino
    E Galligioni
    M Mansutti
    S Tumolo
    A Lucentini
    F Valduga
    S Bartolini
    L Crinò
    P F Conte
    [J]. British Journal of Cancer, 2004, 90 : 31 - 35
  • [27] Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
    Gupta, S
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (02): : 80 - 81
  • [28] Capecitabine plus paclitaxel as first-or second-line therapy: a multicenter phase II study in metastatic breast cancer.
    Meza, LA
    Amin, B
    Hill, T
    Chen, YM
    Petralia, SA
    Gradishar, WJ
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 271 - 271
  • [29] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [30] Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer
    Chitapanarux, Imjai
    Kamnerdsupaphon, Pimkhuan
    Tharavichitkul, Ekasit
    Lorvidhaya, Vicharn
    Trakultivakorn, Hongsin
    Srisukho, Songpol
    Somwangprasert, Areewan
    Watcharachan, Kirati
    Sukthomya, Vimol
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (01) : 76 - 82
12345